Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized observer-blind study of Abbott high-dose trivalent influenza vaccine in adults aged 60 years and older
2024-519743-15-00Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial of Influvac High Dose, influenza vaccine and influenza vaccine (quadrivalent, high-dose) in influenza (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Postvaccination HI geometric mean titers. Started Oct 2025; status: completed.
02
Drugs
Influvac High Doseinfluenza vaccineinfluenza vaccine (quadrivalent, high-dose)
03
Conditions
influenza
Beyond the preview
Go deeper on 2024-519743-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519743-15-00.